Virginia Andreotti

Dr. Virginia Andreotti

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2012 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
Paola GhiorzoPaola Ghiorzo
Paola Ghiorzo
Lorenza PastorinoLorenza Pastorino
Lorenza Pastorino
PQPaola Queirolo
Paola Queirolo
William BrunoWilliam Bruno
William Bruno
MTM. G. Tibiletti
M. G. Tibiletti
GSG. Bianchi Scarrà
G. Bianchi Scarrà

1 February 2002 in BioTechniques
Verified
Journal Article
Open access
BPB. Parodi
B. Parodi
OAO. Aresu
O. Aresu
DBD. Bini
D. Bini
RLR. Lorenzini
R. Lorenzini
FSF. Schena
F. Schena
TRT. Ruzzon
T. Ruzzon
Misidentification and cross-contamination of cell lines are major problems of cell cultures that can make scientific results and their reproducibility unreliable. This paper describes a PCR-based m...

2 June 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VAVirginia Andreotti
Virginia Andreotti
Yari CiribilliYari Ciribilli
Yari Ciribilli
PMPaola Monti
Paola Monti
ABAlessandra BISIO
Alessandra BISIO
MLMattia Lion
Mattia Lion
Alberto IngaAlberto Inga
Alberto Inga
The p53 tumor suppressor, which is altered in most cancers, is a sequence-specific transcription factor that is able to modulate the expression of many target genes and influence a variety of cellular pathways. Inactivation of the p53 pathway in cancer frequently occurs through the expression of mutant p53 protein. In tumors that retain wild type p53, the pathway can be altered by upstream modulators, particularly the p53 negative regulators MDM2 and MDM4. Given the many factors that might influence p53 function, including expression levels, mutations, cofactor proteins and small molecules, we expanded our previously described yeast-based system to provide the opportunity for efficient investigation of their individual and combined impacts in a miniaturized format. The system integrates i) variable expression of p53 proteins under the finely tunable GAL1,10 promoter, ii) single copy, chromosomally located p53-responsive and control luminescence reporters, iii) enhanced chemical uptake using modified ABC-transporters, iv) small-volume formats for treatment and dual-luciferase assays, and v) opportunities to co-express p53 with other cofactor proteins. This robust system can distinguish different levels of expression of WT and mutant p53 as well as interactions with MDM2 or 53BP1. We found that the small molecules Nutlin and RITA could both relieve the MDM2-dependent inhibition of WT p53 transactivation function, while only RITA could impact p53/53BP1 functional interactions. PRIMA-1 was ineffective in modifying the transactivation capacity of WT p53 and missense p53 mutations. This dual-luciferase assay can, therefore, provide a high-throughput assessment tool for investigating a matrix of factors that can influence the p53 network, including the effectiveness of newly developed small molecules, on WT and tumor-associated p53 mutants as well as interacting proteins.

1 February 2016 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
William BrunoWilliam Bruno
William Bruno
Lorenza PastorinoLorenza Pastorino
Lorenza Pastorino
Paola GhiorzoPaola Ghiorzo
Paola Ghiorzo
VAVirginia Andreotti
Virginia Andreotti
CMClaudia Martinuzzi
Claudia Martinuzzi
GBGiovanna Bianchi-Scarrà
Giovanna Bianchi-Scarrà

7 June 2012 in Experimental Dermatology
Verified
Journal Article
Open access
PDF file
Paola GhiorzoPaola Ghiorzo
Paola Ghiorzo
LBLuigina Bonelli
Luigina Bonelli
Lorenza PastorinoLorenza Pastorino
Lorenza Pastorino
William BrunoWilliam Bruno
William Bruno
MBMonica Barile
Monica Barile
PQPaola Queirolo
Paola Queirolo
Host, environmental and genetic factors differently modulate cutaneous melanoma (CM) risk across populations. Currently, the main genetic risk determinants are germline mutations in the major known high-risk susceptibility genes, CDKN2A and CDK4, and variants of the low-risk gene MC1R, which is key in the pigmentation process. This case–control study aimed at investigating the influence of the main host and environmental risk factors and of MC1R variation on CM risk in 390 CDKN2A-negative and 49 CDKN2A-positive Italian individuals. Multivariate analysis showed that MC1R variation, number of nevi and childhood sunburns doubled CM risk in CDKN2A-negative individuals. In CDKN2A-positive individuals, family history of CM and presence of atypical nevi, rather than MC1R status, modified risk (20.75- and 2.83-fold, respectively). Occupational sun exposure increased CM risk (three to sixfold) in both CDKN2A-negative and CDKN2A-positive individuals, reflecting the occupational habits of the Ligurian population and the geographical position of Liguria.

17 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
ABAlessandra BISIO
Alessandra BISIO
ELElisa Latorre
Elisa Latorre
VAVirginia Andreotti
Virginia Andreotti
BPBrigitte Bressac-de Paillerets
Brigitte Bressac-de Paillerets
MHMark Harland
Mark Harland
Alberto IngaAlberto Inga
Alberto Inga
The 5′-untranslated region of p16 INK4 a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding